Your browser doesn't support javascript.
loading
Patients' satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis.
Spessotto, Caroline Vieira; Cavalli, Hanaie; Eboni, Audred Cristina Biondo; Machado, Rafael Berlezi; Mousquer, Analara Munardi; Palazzo, Lara Both; Finkelsztejn, Alessandro; Goncalves, Marcus Vinicius Magno; Sato, Henry Koiti; Siquineli, Fabio; Fragoso, Yara Dadalti.
Afiliação
  • Spessotto CV; Universidade Metropolitana de Santos, Departamento de Neurologia, Santos SP, Brasil;
  • Cavalli H; Residência em Clínica Médica da Angiocorpore, Santos SP, Brasil;
  • Eboni AC; Instituto de Neurologia de Curitiba, Curitiba PR, Brasil;
  • Machado RB; Centro Hospitalar Unimed, Joinville SC, Brasil;
  • Mousquer AM; Hospital de Clinicas de Porto Alegre, Porto Alegre RS, Brasil;
  • Palazzo LB; Universidade Regional de Blumenau, Blumenau SC, Brasil.
  • Finkelsztejn A; Hospital de Clinicas de Porto Alegre, Porto Alegre RS, Brasil;
  • Goncalves MV; Hospital de Clinicas de Porto Alegre, Porto Alegre RS, Brasil;
  • Sato HK; Centro Hospitalar Unimed, Joinville SC, Brasil;
  • Siquineli F; Instituto de Neurologia de Curitiba, Curitiba PR, Brasil;
  • Fragoso YD; Universidade Regional de Blumenau, Blumenau SC, Brasil.
Arq Neuropsiquiatr ; 74(8): 617-20, 2016 Aug.
Article em En | MEDLINE | ID: mdl-27556371
OBJECTIVE: The treatment of multiple sclerosis (MS) with disease-modifying-drugs (DMDs) is evolving and new drugs are reaching the market. Efficacy and safety aspects of the drugs are crucial, but the patients' satisfaction with the treatment must be taken into consideration. METHODS: Individual interview with patients with MS regarding their satisfaction and points of view on the treatment with DMDs. RESULTS: One hundred and twenty eight patients attending specialized MS Units in five different cities were interviewed. Over 80% of patients were very satisfied with the drugs in use regarding convenience and perceived benefits. The only aspect scoring lesser values was tolerability. CONCLUSION: Parameters for improving treatment in MS must include efficacy, safety, and patient satisfaction with the given DMD.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Satisfação do Paciente / Imunossupressores / Esclerose Múltipla Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Satisfação do Paciente / Imunossupressores / Esclerose Múltipla Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article